Explore the Global Inherited Retinal Diseases Treatment Market — analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036.

Future Market Insights

Inherited Retinal Diseases Treatment Market

Key Insight

Inherited retinal diseases treatment sales will strengthen through 2036, anchored by gene therapy treatment at a 57.6% share in 2026 as the leading treatment type segment. The market was valued at USD 12.6 billion in 2025 and is expected to reach USD 30.91 billion by 2036, creating an incremental opportunity of USD 17.24 billion.

May 19, 2026

Anurag Sharma

275 Pages

Cite this Report

Inherited Retinal Diseases Treatment Market

https://www.futuremarketinsights.com/reports/inherited-retinal-diseases-treatment-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

Astellas Pharma Inc
Biogen Inc
The Vanguard Group
Novartis
Regeneron Pharmaceuticals
Roche
Spark Therapeutics

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Inherited Retinal Diseases Treatment Market

Key Players

Similar Industry Reports